CBD for Epilepsy Finally Has Hard Evidence, but a Drug Interaction Complicates the Picture
Three placebo-controlled trials confirmed that pharmaceutical CBD reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome, but a significant drug interaction with clobazam makes it unclear whether the benefits come from CBD itself or from elevated levels of the co-medication.
Quick Facts
What This Study Found
After years of uncontrolled observations and anecdotal reports, three rigorous placebo-controlled trials of purified CBD (Epidiolex) provided the first class 1 evidence that CBD improves seizure control in specific epilepsy syndromes.
In Dravet syndrome, CBD reduced the frequency of convulsive seizures (tonic-clonic, tonic, clonic, and atonic) compared to placebo. In Lennox-Gastaut syndrome, CBD reduced the frequency of drop seizures.
However, the review raises a critical complication: CBD markedly increases plasma levels of N-desmethylclobazam, the active metabolite of clobazam, a commonly co-prescribed anti-seizure medication. Many trial participants were taking clobazam, meaning some of the observed seizure reduction could be due to this drug interaction rather than a direct anti-seizure effect of CBD. The author argues that subgroup analyses of patients not taking clobazam are needed to resolve this question.
Key Numbers
Three placebo-controlled trials completed. CBD reduced convulsive seizures in Dravet syndrome and drop seizures in Lennox-Gastaut syndrome vs. placebo. CBD significantly increased N-desmethylclobazam plasma levels in patients co-medicated with clobazam.
How They Did This
Comprehensive narrative review covering the preclinical anticonvulsant profile of CBD, uncontrolled clinical observations with CBD-enriched extracts, and the three pivotal placebo-controlled adjunctive-therapy trials in Dravet syndrome and Lennox-Gastaut syndrome.
Why This Research Matters
This review marks a turning point in the evidence base for CBD in epilepsy. For the first time, controlled trial evidence confirmed what families and clinicians had reported anecdotally for years. But the author's identification of the clobazam interaction as a potential confound is important: if a significant portion of the benefit comes from boosted clobazam levels, then CBD's direct anti-seizure effect may be smaller than the headline results suggest.
The Bigger Picture
The CBD-epilepsy story illustrates both the promise and complexity of cannabinoid medicine. Hard evidence arrived, confirming real clinical benefit, but also revealed pharmacological nuances (drug interactions) that complicate interpretation. This pattern of "it works, but the mechanism may not be what we assumed" is a recurring theme in cannabinoid research.
What This Study Doesn't Tell Us
The review is authored by a single expert and is not a formal systematic review. The clobazam interaction concern, while scientifically valid, has not been definitively resolved by the time of this review. The trials studied pharmaceutical-grade CBD, not over-the-counter CBD products, which vary widely in quality and composition.
Questions This Raises
- ?How much of CBD's anti-seizure effect is direct versus mediated through boosted clobazam levels?
- ?Does CBD reduce seizures in patients not taking clobazam?
- ?Are CBD-enriched extracts (containing trace amounts of other cannabinoids) more effective than purified CBD alone?
Trust & Context
- Key Stat:
- First class 1 evidence that CBD reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome
- Evidence Grade:
- Strong evidence: the review covers three placebo-controlled randomized trials providing class 1 evidence, though with the clobazam interaction caveat.
- Study Age:
- Published in 2017, shortly after the pivotal trials that led to Epidiolex FDA approval in 2018.
- Original Title:
- Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
- Published In:
- Journal of epilepsy research, 7(2), 61-76 (2017)
- Authors:
- Perucca, Emilio(6)
- Database ID:
- RTHC-01484
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does CBD work for all types of epilepsy?
The controlled trial evidence at the time of this review was specific to Dravet syndrome and Lennox-Gastaut syndrome, both severe childhood epilepsy syndromes. Whether CBD helps other epilepsy types was not established by these trials.
What is the clobazam interaction and why does it matter?
CBD significantly increases blood levels of N-desmethylclobazam, the active breakdown product of the anti-seizure drug clobazam. Since many trial participants were taking clobazam, some of the seizure reduction attributed to CBD may actually have resulted from having more clobazam metabolite in their system. This makes it harder to know how much benefit comes from CBD directly.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01484APA
Perucca, Emilio. (2017). Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. Journal of epilepsy research, 7(2), 61-76. https://doi.org/10.14581/jer.17012
MLA
Perucca, Emilio. "Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?." Journal of epilepsy research, 2017. https://doi.org/10.14581/jer.17012
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in the Treatment of Epilepsy: Hard Evidence at ..." RTHC-01484. Retrieved from https://rethinkthc.com/research/perucca-2017-cannabinoids-in-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.